Area of research
Infectious Diseases · Epidemiology
Research interest
Research focused on Compatibility (geochemistry) and In vivo, with related work in Pharmacokinetics, Pharmacology, Virus. Notable publications include 'Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir', 'Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro', and 'Liang–Ge–San protects against viral infection-induced acute lung injury through inhibiting α7nAChR-mediated mitophagy'.
Post-influenza bacterial infection: mechanisms of pathogenesis and advances in therapeutic strategies
Multi-dimensional PK-PD insights into Lianhua Qingwen's formula compatibility
Multi-Dimensional Pk-Pd Insights into Lianhua Qingwen's Formula Compatibility
Elucidating Forsythin’s Anti-Inflammatory Action Through Modulation of the P38 MAPK Pathway in SARS-CoV-2 Infection
Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
Liang–Ge–San protects against viral infection-induced acute lung injury through inhibiting α7nAChR-mediated mitophagy
Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-19
Liushen Wan alleviates the virulence and inflammation of Staphylococcus aureus via NLRP3 inflammasome and TLR2-NF-κB/p38 MAPK signaling pathways
Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro
Investigating the effects of Liushen Capsules (LS) on the metabolome of seasonal influenza: A randomized clinical trial